• Change country/language

    Looks like you’re in {} — you’re on the {} site.

    Cancel

    Country and language selected

    You are being redirected to the {} site. Products and services availability vary by country. Do you wish to continue?

    Continue
    Cancel

Omnipaque™ (lohexol)

Administered since 1982, this low osmolar contrast agent is indicated for intravenous, intra-arterial, intrathecal, body cavity and oral use in gastro-intestinal studies¹

JB02159UK Omnipaque  Hero Image 1  Desktop 72dpi 1920x810pix 2

Scan after scan

Every 2 seconds, 5 patient procedures are performed using Omnipaque™²

Prescribing confidence

No LOCM was better tolerated than Omnipaque in a prospective, randomized study of 8,931 CT patients³

Enhancing oral procedures

Patients preferred the taste of Omnipaque over barium sulfate contrast

Promoting workflow efficiency

Omnipaque is available in a range of bottle sizes to suit clinical needs

About Omnipaque
Omnipaque has been unsurpassed by any low-osmolar contrast media for either diagnostic efficacy or tolerability at equi-attenuating doses in head-to-head trials.12-22
Patient after patient
Omnipaque provides reliabilty and choice
• Indicated for intravenous, intra-arterial, body cavity, intrathecal and oral uses¹
• Approved for use in both adults and children¹
Feature-Hero-Image1-Patient-after-patient-Image-72dpi-1650x1100pix-1-85
Scan after scan
Prescribing confidence with Omnipaque
In a prospective, randomized study of 8,391 CT patients, no LOCM was better tolerated than Omnipaque³
Omnipaque-Feature-Hero-Image-2-Scan-after-scan-72dpi-1650x1100pix-1-2-80
Taste after taste
Enhancing oral procedures
• 81% of adult body CT patients, who expressed a preference, preferred Omnipaque over diatrizoate⁶
• 98% of paediatric patients undergoing abdominal CT, many of whom were under 5, drank the required volume of Omnipaque⁷
Omnipaque-Feature-Hero-Image-3-Taste-after-taste-72dpi-1650x1100pix-1-2-79
Bottle after bottle
Omnipaque's +PLUSPAK packaging support departmental efficiency
• Colour coded labelling to prevent administration errors
• Important information to be is repeated upside down so it's easier to read at any angle
• Reducing hazard and downtime with no more broken bottles and injuries from the ring pulls⁸
• Reducing costs and environment impact with less storage space and lower disposal costs⁸⁻¹⁰
OmnipaqueFeatureHero_1
Scan after scan
Supporting patient throughput with Omnipaque 500mL capacity
• Omnipaque 500mL can be used for up to 24 hours from initial puncture. Chemical and physical stability has been demonstrated for 24 hours at 25˚C¹
• Omnipaque 500mL can aid with effficency with fewer bottle changes 11
• Omnipaque 500mL can aid economy by reducing the number of bottle spikes used11
• Omnipaque 500mL should only be used in connection with auto injectors/pumps approved for this volume1.
JB02159UKOmnipaqueFeatureHeroImage5Scanafterscan72dpi1650x1100pix2

Prescribing Information

Please click here for Omnipaque prescribing information
 

Adverse events should also be reported to GE HealthCare at:
IndiaAdverse.events@gehealthcare.com

References
  1. UK Omnipaque Summary of Product Characteristics, January 2023
  2. Data on File, GE HealthCare, Omnipaque Demand_2022
  3. Gomi T et al. Eur Radiol 2010; 10(7):1631-5
  4. Parakh A et al. Radiology 2019; 291(3): 620-29
  5. McNamara M et al. Am J Roentgenol 2010; 195: 1137–41.
  6. Smevik B, Westvik J. Acta Radiol 1990; 31: 601–4.
  7. Marshall G. Radiography 2008; 14:128-34
  8. Gricar J et al. Radiology Management 2007: Sept/Oct 34-42
  9. Dhaliwal H et al. Int J Life Cycle Assess (2014) 19:1965-73
  10. Sudgen D. Presented at UK North CT Radiographer Work. Leeds, March 2017
  11. Lamb JT. Invest Radiol 1985; 20(Suppl.) S37–S43.
  12. Rubin CME et al. Brit J Radiol 1987; 60: 133–5.
  13. Harding JR et al. Brit J Radiol 1995; 68: 712–5.
  14. Katayama H et al. Invest Radiol 2001; 36: 22–32.
  15. Faykus MH et al. Invest Radiol 1994; 29 (Suppl.1): S98–S101.
  16. Bischoff W. Fortschr Röntgenstr 1989; 128: 108–10.
  17. Drouillard J et al. Acta Radiol 1996; 37 (Suppl.400): 56–61.
  18. Legmann P et al. Eur Radiol 2001; 11: 2220–7.
  19. Kaufman AJ et al. Urol Radiol 1990; 12: 56–60.
  20. Cutcliff WB et al. Invest Radiol 1989; 24 (Suppl.1): S56–9.
  21. Bertrand P et al. Acad Radiol 1995; 2: 683–6.
  22. Krouwels MM et al. Eur J Radiol 1996; 22: 133–5.

02-2023 JB00302BS

Have a question? We would love to hear from you.

We're ready to support you in your moments that matter.

Thank you!

We received your request for assistance.

A GE Healthcare specialist will be reaching out shortly.

Something went wrong

We will check and get back.

JB00302BS July 2024